Riverwater Partners Small Cap Strategy Sold Its Stake in Haemonetics Corporation (HAE) in Q3

Core Insights - Riverwater Partners' Small Cap Strategy reported solid results for Q3 2025 but lagged behind the benchmark due to the market's preference for lower-quality companies [1] - The strategy focuses on higher-quality companies with strong fundamentals and a clear path to profitability, positioning itself well in a challenging market [1] Company Performance - Haemonetics Corporation (NYSE:HAE) had a one-month return of 8.06% but experienced a 2.03% decline over the last 52 weeks, closing at $80.40 per share with a market capitalization of $3.873 billion [2] - The company faced challenges due to softer-than-expected demand in certain product lines, leading to a decision to exit the position in Q3 2025 to redeploy capital into opportunities with clearer near-term catalysts [3] Revenue and Market Position - In Q2 of fiscal 2026, Haemonetics reported revenue of $327 million, reflecting a 5% decline [4] - Despite its potential, Haemonetics is not among the most popular stocks among hedge funds, with 36 hedge fund portfolios holding its shares at the end of Q3, up from 29 in the previous quarter [4]